JP Morgan Chase
COGT icon

JP Morgan Chase’s Cogent Biosciences COGT Stock Holding History

JP Morgan Chase’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.3M Sell
262,704
-138,227
-34% -$5.1M ﹤0.01% 2754
2025
Q4 		$14.2M Buy
400,931
+326,119
+436% +$9.17M ﹤0.01% 2372
2025
Q3 		$1.07M Buy
74,812
+5,533
+8% +$65.6K ﹤0.01% 4531
2025
Q2 		$497K Sell
69,279
-5,865
-8% -$32.5K ﹤0.01% 4789
2025
Q1 		$450K Buy
75,144
+13,684
+22% +$107K ﹤0.01% 4848
2024
Q4 		$479K Sell
61,460
-3,368
-5% -$33.6K ﹤0.01% 5063
2024
Q3 		$700K Buy
64,828
+5,720
+10% +$55.7K ﹤0.01% 4698
2024
Q2 		$498K Sell
59,108
-27,496
-32% -$209K ﹤0.01% 4691
2024
Q1 		$582K Sell
86,604
-36,590
-30% -$226K ﹤0.01% 4699
2023
Q4 		$724K Sell
123,194
-145,417
-54% -$1.11M ﹤0.01% 4548
2023
Q3 		$2.62M Buy
268,611
+1,953
+0.7% +$23.2K ﹤0.01% 3353
2023
Q2 		$3.16M Sell
266,658
-2,835
-1% -$32.5K ﹤0.01% 3212
2023
Q1 		$2.91M Buy
269,493
+28,073
+12% +$359K ﹤0.01% 3266
2022
Q4 		$2.79M Buy
241,420
+12,578
+5% +$156K ﹤0.01% 3306
2022
Q3 		$3.41M Sell
228,842
-127,066
-36% -$1.74M ﹤0.01% 3046
2022
Q2 		$3.21M Buy
355,908
+192,107
+117% +$1.31M ﹤0.01% 3162
2022
Q1 		$1.23M Sell
163,801
-52,644
-24% -$367K ﹤0.01% 4121
2021
Q4 		$1.86M Buy
216,445
+23,120
+12% +$201K ﹤0.01% 3919
2021
Q3 		$1.63M Buy
193,325
+24,104
+14% +$185K ﹤0.01% 3945
2021
Q2 		$1.37M Sell
169,221
-78,947
-32% -$667K ﹤0.01% 4071
2021
Q1 		$2.18M Buy
248,168
+180,954
+269% +$1.74M ﹤0.01% 3660
2020
Q4 		$755K Buy
+67,214
New +$739K ﹤0.01% 4126
2020
Q1 		– Sell
-60
Closed – – 5348
2019
Q4 		$0 Buy
+60
New +$245 ﹤0.01% 5629
2019
Q2 		– Sell
-1,161
Closed -$20K – 5785
2019
Q1 		$20K Sell
1,161
-8,416
-88% -$144K ﹤0.01% 5405
2018
Q4 		$168K Buy
9,577
+4,389
+85% +$130K ﹤0.01% 4658
2018
Q3 		$213K Buy
5,188
+5,008
+2,782% +$282K ﹤0.01% 4669
2018
Q2 		$10K Buy
+180
New +$8.65K ﹤0.01% 5369

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

JP Morgan Chase's COGT Position: Q1 2026 in Review

JP Morgan Chase reduced its Cogent Biosciences (COGT) stake by 34% in Q1 2026, selling an estimated $5.1M and leaving 262,704 shares worth $9.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

JP Morgan Chase first reported a position in COGT in Q2 2018 and has held it in 27 quarters since. The position peaked at $14.2M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • JP Morgan Chase held 262,704 shares of Cogent Biosciences worth $9.3M as of Q1 2026.
  • JP Morgan Chase sold 138,227 Cogent Biosciences shares in Q1 2026, an estimated $5.1M.
  • Cogent Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2754 holding.
  • JP Morgan Chase first reported a position in Cogent Biosciences in Q2 2018 and has held it in 27 quarters since.
  • JP Morgan Chase's Cogent Biosciences position peaked at $14.2M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.